3.4.22.26: cancer procoagulant

This is an abbreviated version!
For detailed information about cancer procoagulant, go to the full flat file.

Word Map on EC 3.4.22.26

3.4.22.26

coagulation

proteinase

thromboembolic

clot

thrombosis

intravascular

gordon

amnion-chorion

hypercoagulability

thrombin-antithrombin

thrombogenic

three-stage

prothrombotic

warfarin

benson

anti-cp

k-dependent

haemostatic

x-activating

medicine

Reaction

specific cleavage of Arg-/-Ile bond in Factor X to form Factor Xa =

Synonyms

cancer procoagulant, CP

ECTree

3 Hydrolases

3.4 Acting on peptide bonds (peptidases)

3.4.22 Cysteine endopeptidases

3.4.22.26 cancer procoagulant

Advanced search results

Do not include text mining results

Include

results (more...)

Include

results (more...)

Results	in table
11	Activating Compound
2	Application
1	CAS Registry Number
513	Disease/ Diagnostics
1	Expression
6	General Information
6	General Stability
1	IC50 Value
90	Inhibitors
5	kcat/KM [mM/s]
1	Ki Value [mM]
11	KM Value [mM]
7	Localization
32	Metals/Ions
6	Molecular Weight [Da]
25	Natural Substrates/ Products (Substrates)
24	Organism
2	Oxidation Stability
7	pH Optimum
1	pI Value
6	Posttranslational Modification
11	Purification (Commentary)
1	Reaction
6	Reaction Type
24	Reference
62	Source Tissue
32	Specific Activity [micromol/min/mg]
1	Storage Stability
97	Substrates and Products (Substrate)
5	Subunits
14	Synonyms
6	Temperature Optimum [°C]
10	Turnover Number [1/s]

IC50 Value

print visible entries

print all entries

Go back to the abbreviated version
of the Enzyme Summary Page.

IC50 Value on EC 3.4.22.26 - cancer procoagulant

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.

top print hide

Go to IC50 Value Search

additional information

Rattus norvegicus

cancer procoagulant activity from 4 independent prostate tumors is assayed, inhibition of FX-activating activity of cancer procoagulant-containing extracts by use of a polyclonal antiFVIIa antibody, samples obtained from 1-step purification of crude extract are tested for the presence of tissue factor or FVIIa activity in inhibition assay using antirat factor VIIa polyclonal antibodies, 0% inhibition of cancer procoagulant sample 1, 0.4% inhibition of cancer procoagulant sample 2, 6.6% inhibition of cancer procoagulant sample 3, 4.9% inhibition of cancer procoagulant sample 4

697471